Mirae Asset Global Investments Co. Ltd. Reduces Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Mirae Asset Global Investments Co. Ltd. reduced its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 15.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 130,858 shares of the medical device company's stock after selling 23,457 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.20% of Tandem Diabetes Care worth $3,896,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. State of Wyoming lifted its holdings in Tandem Diabetes Care by 45.8% during the 4th quarter. State of Wyoming now owns 821 shares of the medical device company's stock valued at $37,000 after purchasing an additional 258 shares during the last quarter. RiverPark Advisors LLC acquired a new stake in Tandem Diabetes Care in the 4th quarter valued at about $27,000. Stephens Inc. AR increased its position in Tandem Diabetes Care by 17.6% in the 1st quarter. Stephens Inc. AR now owns 2,120 shares of the medical device company's stock valued at $86,000 after acquiring an additional 317 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in Tandem Diabetes Care in the 1st quarter valued at about $256,000. Finally, Lazard Asset Management LLC increased its position in Tandem Diabetes Care by 174.5% in the 1st quarter. Lazard Asset Management LLC now owns 2,616 shares of the medical device company's stock valued at $304,000 after acquiring an additional 1,663 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on TNDM shares. Stifel Nicolaus upgraded shares of Tandem Diabetes Care from a "hold" rating to a "buy" rating and raised their price objective for the company from $24.00 to $37.00 in a research report on Tuesday, March 26th. Citigroup raised their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research report on Wednesday, April 3rd. Finally, StockNews.com cut shares of Tandem Diabetes Care from a "hold" rating to a "sell" rating in a research report on Thursday, April 11th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $37.00.

Tandem Diabetes Care Trading Down 3.7 %

NASDAQ TNDM traded down $1.21 during trading on Wednesday, reaching $31.75. 1,053,076 shares of the stock traded hands, compared to its average volume of 1,761,615. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -9.23 and a beta of 1.12. The stock's 50-day moving average price is $29.64 and its 200 day moving average price is $24.76. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91. Tandem Diabetes Care, Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $41.92.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). The firm had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. Analysts predict that Tandem Diabetes Care, Inc. will post -1.62 EPS for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.